Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells.
作者： Paolina Pantcheva , Stephanny Reyes , Jaclyn Hoover , Sussannah Kaelber , Cesar V Borlongan
DOI: 10.1586/14737175.2015.1091727
关键词:
摘要: Parkinson's disease (PD) treatment-based research has focused on developing therapies for the management of motor symptoms. Non-motor symptoms do not respond to treatments targeting deficits, thus necessitating an urgent need develop new modalities that cater both and non-motor deficits. Stem cell transplantation is potentially therapeutic PD, but have been primarily neglected in such therapy regimens. Many types stem cells are currently available therapy, including adult tissue (e.g., bone marrow, placenta)-derived mesenchymal cells. The fact can replace rescue degenerated dopaminergic non-dopaminergic suggests their potential treatment as well which discussed this article.
sci-hub.se 参考文章(89)
Ricardo Pardal, José López-Barneo, Neural stem cells and transplantation studies in Parkinson's disease Advances in Experimental Medicine and Biology. ,vol. 741, pp. 206- 216 ,(2012) , 10.1007/978-1-4614-2098-9_14
Cesario V. Borlongan, Christine E. Stahl, Don F. Cameron, Samuel Saporta, Thomas B. Freeman, David W. Cahill, Paul R. Sanberg, CNS IMMUNOLOGICAL MODULATION OF NEURAL GRAFT REJECTION AND SURVIVAL Neurological Research. ,vol. 18, pp. 297- 304 ,(1996) , 10.1080/01616412.1996.11740425
N M Berezetskaia, E P Lukhanina, I N Karaban, N A Mel'nik, Iu A Burenok, [Effect of cerebrolysin on the electroencephalographic indices of brain activity in Parkinson's disease]. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. ,vol. 104, pp. 54- 60 ,(2004)
Marios Politis, Paola Piccini, In vivo imaging of the integration and function of nigral grafts in clinical trials. Progress in Brain Research. ,vol. 200, pp. 199- 220 ,(2012) , 10.1016/B978-0-444-59575-1.00009-0
Mesenchymal Stem Cells - Basics and Clinical Application II Springer. ,(2013) , 10.1007/978-3-642-35671-1
Omar Abdel-Salam, Drugs used to treat Parkinson's disease, present status and future directions. Cns & Neurological Disorders-drug Targets. ,vol. 7, pp. 321- 342 ,(2008) , 10.2174/187152708786441867
Jeffrey H. Kordower, Thomas B. Freeman, Er-Yun Chen, Elliott J. Mufson, Paul R. Sanberg, Robert A. Hauser, Barry Snow, C. Warren Olanow, Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease Movement Disorders. ,vol. 13, pp. 383- 393 ,(1998) , 10.1002/MDS.870130303
Zacharias Kohl, Beate Winner, Kiren Ubhi, Edward Rockenstein, Michael Mante, Martina Münch, Carolee Barlow, Todd Carter, Eliezer Masliah, Jürgen Winkler, Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model European Journal of Neuroscience. ,vol. 35, pp. 10- 19 ,(2012) , 10.1111/J.1460-9568.2011.07933.X
David S. Goldstein, Dysautonomia in Parkinson Disease Comprehensive Physiology. ,vol. 4, pp. 805- 826 ,(2014) , 10.1002/CPHY.C130026
Maria Sundberg, Helle Bogetofte, Tristan Lawson, Johan Jansson, Gaynor Smith, Arnar Astradsson, Michele Moore, Teresia Osborn, Oliver Cooper, Roger Spealman, Penelope Hallett, Ole Isacson, Improved Cell Therapy Protocols for Parkinson's Disease Based on Differentiation Efficiency and Safety of hESC-, hiPSC-, and Non-Human Primate iPSC-Derived Dopaminergic Neurons† Stem Cells. ,vol. 31, pp. 1548- 1562 ,(2013) , 10.1002/STEM.1415